Mineralys Therapeutics, Inc.
Public company- Headquarters
- RADNOR, Pennsylvania
- Ticker
- MLYS
- CIK
- 0001933414
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| DirectorDerek DiRocco, Ph.D. | Nov 4, 2026 | Departed |
| Class I directorKristine Peterson | Oct 19, 2026 | Appointed |
| Class II directorLonnel Coats | Oct 19, 2026 | Appointed |
| CMOJames J. Ferguson III, M.D. | Aug 11, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- MADRIGAL PHARMACEUTICALS, INC.
Class II director appointed: John C. Reed, M.D., Ph.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Merck & Co., Inc.
WARN notice: Rahway, NJ
- Executive departure
Director departs: Derek DiRocco, Ph.D.
Derek DiRocco, Ph.D., Director of Mineralys Therapeutics, Inc., resigns the role, effective December 31, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 4, 2026Role: Director
- Executive appointment
Class I director appointed: Kristine Peterson
Kristine Peterson was named Class I director of Mineralys Therapeutics, Inc., effective October 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 19, 2026Role: Class I director
- Executive appointment
Class II director appointed: Lonnel Coats
Lonnel Coats was named Class II director of Mineralys Therapeutics, Inc., effective October 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 19, 2026Role: Class II director
- Executive appointment
CMO appointed: James J. Ferguson III, M.D.
James J. Ferguson III, M.D. was named Chief Medical Officer of Mineralys Therapeutics, Inc., effective August 10, 2026. James J. Ferguson III, M.D. succeeds David Rodman, M.D.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 11, 2026Role: Chief Medical Officer
Last verified Nov 8, 2026